{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-008833","form_type":"8-K/A","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.537878+00:00","generated_at":"2026-06-02T03:52:19.715296+00:00","sec_items":["1.01","3.02","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alzamend Neuro raises up to $25M via Series A Preferred and warrants; initial $500K closed","bullets":["Up to $25 million financing via Series A Convertible Preferred Stock and warrants; initial tranche of $500,000 closed May 10, 2024.","Series A Preferred: $10,000 stated value per share, 15% cumulative annual dividend payable quarterly in cash or shares at investor’s option.","Conversion price is the greater of $0.25 floor or the lesser of $1.50 and 80% of the 3-day VWAP; anti-dilution adjustment applies.","Warrants: exercise price $1.25, 5-year term; 800,000 warrant shares issued in initial tranche. Exercise price adjustable for stock splits.","Stockholder approval required for any conversion/warrant exercise exceeding 19.99% of outstanding common shares; proxy statement to be filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-008833","json":"https://secwatch.observer/filing/0001214659-24-008833.json","markdown":"https://secwatch.observer/filing/0001214659-24-008833.md","text":"https://secwatch.observer/filing/0001214659-24-008833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/0001214659-24-008833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/x592418ka1.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:52:19.715296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb8bb119a9bfd4c9c575e7b26f0f89b1126e8dff","claim":"Alzamend Neuro, Inc.: Company filed Certificate of Designation for Series A Preferred Stock (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, the Company filed the Certificate designating 3,000 shares of Series A Preferred Stock, with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/0001214659-24-008833-index.htm","confidence":0.7,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-05-09"}]},{"claim_id":"952d29b9eaf013a475fc1310b072b6df7aaefb0d","claim":"Alzamend Neuro, Inc. entered into Securities Purchase Agreement with a sophisticated investor valued at up to $25,000,000.00 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to sell to the Purchaser up to 2,500 shares of Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) and warrants (the “ Warrants ”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) for a total purchase price of up to $25,000,000.00 (the “ Financing ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/0001214659-24-008833-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a sophisticated investor"},{"label":"Value","value":"up to $25,000,000.00"},{"label":"Effective","value":"2024-05-08"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}